Masimo's Revenue in the fiscal year 2025 $ 1,526.20 millions
Masimo's Revenue in the fiscal year 2024 $ 2,094.40 millions
Masimo's Revenue in the fiscal year 2023 $ 2,047.50 millions
Masimo's Revenue in the fiscal year 2022 $ 2,035.80 millions
Masimo's Revenue in the fiscal year 2021 $ 1,239.15 millions
MASI Revenue first quarter 2026 Y/Y Growth Comment
Masimo Corp achieved in the first quarter 2026, above Company average Revenue improvement of 8.28% year on year, to $ 402.80 millions.
Looking into first quarter 2026 results within Medical Equipment & Supplies industry 96 other companies have achieved higher Revenue growth. While Masimo Corp' s Revenue increase of 8.28% ranks overall at the positon no. 1865 in the first quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Masimo's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
85.77 %
-5.19 %
-100 %
(Jul 02 2022)
MASI's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Masimo Corp disclosed fall in Revenue from the fourth quarter by -2.54% to $ 402.80 millions, from $ 413.30 millions achived in the previous reporting period.
But that's not important problem, as Masimo's Revenue generally seem to plunge in this quarter.
Within Medical Equipment & Supplies industry 69 other companies have achieved higher Revenue quarter on quarter growth. While Masimo's Revenue growth quarter on quarter, overall rank is 1999.
In the I. Quarter 2026 Masimo Corp disclosed fall in Revenue from the fourth quarter by -2.54% to $ 402.80 millions, from $ 413.30 millions achived in the previous reporting period.
But that's not important problem, as Masimo's Revenue generally seem to plunge in this quarter.
Within Medical Equipment & Supplies industry 69 other companies have achieved higher Revenue quarter on quarter growth. While Masimo's Revenue growth quarter on quarter, overall rank is 1999.
Masimo's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Apr 04 2026)
12 Months Ending (Jan 03 2026)
12 Months Ending (Sep 27 2025)
12 Months Ending (Jun 28 2025)
12 Months Ending (Mar 29 2025)
Cumulative Revenue 12 Months Ending
$ 1,557.00
$ 1,526.20
$ 1,714.60
$ 1,848.20
$ 1,973.70
Y / Y Revenue Growth (TTM)
-21.11 %
-27.13 %
-16.01 %
-8.32 %
-0.09 %
Year on Year Revenue Growth Overall
Ranking
# 2645
# 2003
# 2464
# 2612
# 1090
Seqeuential Revenue Change (TTM)
2.02 %
-10.99 %
-7.23 %
-6.36 %
-5.76 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 3045
# 1969
# 2056
# 1876
# 951
Cumulative Revenue growth Comment
Masimo showed decline, but improvement compare to trailing twelve month Revenue decrease in Jan 03 2026. If the fiscal year would end in Apr 04 2026, Masimo's annual Revenue decline would be -21.11% year on year to $1,557 millions.
In the Healthcare sector 378 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2003 to 2645.
Masimo showed decline, but improvement compare to trailing twelve month Revenue decrease in Jan 03 2026. If the fiscal year would end in Apr 04 2026, Masimo's annual Revenue drop would be -21.11% year on year to $1,557 millions.
In the Healthcare sector 378 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2003 to 2645.
About Masimo Revenue Growth Rates (MASI), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
11.99%